Literature DB >> 6499862

Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure.

R Y Wang, J S Chow, K H Chan, H Y Pan, R P Wong.   

Abstract

The acute haemodynamic and myocardial metabolic effects of intravenous urapidil were evaluated in 12 patients with severe congestive heart failure due to coronary heart disease. Urapidil was given intravenously (0.5 mg kg-1 min-1 as a bolus) followed by infusion at a rate of 4 micrograms kg-1 min-1 for 120 min. Following urapidil administration, cardiac index increased by 29%, mean pulmonary artery wedge pressure fell by 35% and systemic vascular resistance by 33%. The fall in mean arterial pressure was moderate. No significant alterations in coronary sinus blood flow, myocardial oxygen consumption and myocardial lactate extraction occurred. No untoward effect was observed. This study shows that intravenous urapidil produces beneficial haemodynamic effects without a deleterious effect on myocardial metabolism in patients with heart failure due to coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499862     DOI: 10.1093/oxfordjournals.eurheartj.a061736

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Human pharmacology of urapidil.

Authors:  A M Shepherd
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Haemodynamic effects of urapidil in arterial hypertension and congestive heart failure.

Authors:  F H Messerli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Effect of urapidil on the performance of ischemic myocardium in anesthetized dogs.

Authors:  H Schad; W Heimisch; A Barankay; S Hesse; N Mendler
Journal:  Basic Res Cardiol       Date:  1990 May-Jun       Impact factor: 17.165

4.  Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure.

Authors:  U Tebbe; W Wurst; K L Neuhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  The nitura study--effect of nitroglycerin or urapidil on hemodynamic, metabolic and respiratory parameters in hypertensive patients with pulmonary edema.

Authors:  W Schreiber; C Woisetschläger; M Binder; A Kaff; H Raab; M M Hirschl
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

Review 6.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

7.  The assessment of the beta-blocking activity of urapidil: a new method.

Authors:  M J Jamieson; S H Jackson; S S Patel; A M Shepherd; H Galbraith; W Stewart; P H Flanagan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Guidelines for the drug treatment of hypertensive crises.

Authors:  M M Hirschl
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

9.  Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.

Authors:  Wei Yang; Yu Jie Zhou; Yan Fu; Jian Qin; Shu Qin; Xiao Min Chen; Jin Cheng Guo; De Zhao Wang; Hong Zhan; Jing Li; Jing Yu He; Qi Hua
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

10.  Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial.

Authors:  Wei Yang; Yu-Jie Zhou; Yan Fu; Jian Qin; Shu Tan; Xiao-Min Chen; Jin-Cheng Guo; DE-Zhao Wang; Hong Zhan; Wei Guan; Ya-Wei Xu; Jing-Yu He; Jing Li; Q I Hua
Journal:  Exp Ther Med       Date:  2016-04-27       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.